India’s top drugmaker Cipla is emerging as an attractive takeover candidate, owing to its strong presence in respiratory, anti-infectives, anti-aids drugs and chronic diseases drugs.
The Mint reports that Mukesh Ambani’s Reliance Life Sciences is in talks to acquire Cipla to expand its portfolio. RLS intends to enter generic space and is choosing an inorganic route for expansion.
It would also make strategic sense for Reliance as it can be an effective feed to the expansion of Reliance Retail pharmacy stores.
Earlier, there were reports of a deal brewing between Glaxo Smithkiline UK and Cipla for sourcing of inhalation devices. Cipla is known globally for its inhalation products manufactured at cheap costs.